DP2- ECONOMIC IMPACT OF PROZAC PATENT EXPIRATION AND THE 180-DAY GENERIC FLUOXETINE EXCLUSIVITY IN A PUBLICLY-FINANCED PRESCRIPTION PROGRAM
May 1, 2003, 00:00
10.1016/S1098-3015(10)63837-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)63837-5/fulltext
Title :
DP2- ECONOMIC IMPACT OF PROZAC PATENT EXPIRATION AND THE 180-DAY GENERIC FLUOXETINE EXCLUSIVITY IN A PUBLICLY-FINANCED PRESCRIPTION PROGRAM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63837-5&doi=10.1016/S1098-3015(10)63837-5
First page :
Section Title :
Open access? :
No
Section Order :
37